20 articles
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
Researchers discover unique molecular patterns in lipedema patients and develop predictive models for this poorly understood condition affecting women.
Two bacterial proteins that sense sulfur compounds unexpectedly regulate nitrate removal, revealing new targets for optimizing wastewater treatment.
Master the advanced molecular architecture of AMPK — from isoform-specific signaling and spatial compartmentalization to emerging pharmacological strategies targeting the energy sensor at the heart of longevity biology.
Transcriptomic analysis of Pseudomonas nitroreducens TX1 identifies 241 differentially expressed genes during surfactant degradation.
New research reveals how obesity during pregnancy triggers genetic changes that cause lasting muscle dysfunction in offspring.
A novel conjugate merges GLP-1/GIP incretin signaling with pan-PPAR activation in one molecule, potentially revolutionizing metabolic therapy.
Brief weekly PEMF exposures increased quail embryo weight by ~20%, body length by ~15%, and upregulated key oxidative muscle genes.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
An erratum to a 2022 Cell Metabolism paper describing a bone marrow lipolytic factor that links mechanical force to bone formation and lymphocyte production.
New research reveals genetic factors that determine individual responses to weight-loss medications like semaglutide.
Deep dive into the master regulatory pathways controlling mitochondrial biogenesis, quality control, and cellular energy homeostasis through PGC-1α coordination.
50 nm polystyrene nanoplastics accumulate in mouse testes, degrading sperm quality and triggering iron-dependent cell death through a newly identified mitochondrial pathway.
The FDA reportedly approved Eli Lilly's orforglipron, a daily oral GLP-1 receptor agonist for obesity, marking a potential shift from injectable weight-loss drugs.
New research validates high-throughput methods for studying mitochondrial dysfunction in malignant hyperthermia susceptibility.
Large NHANES study reveals metabolic syndrome causes measurable acceleration in epigenetic aging clocks, offering new targets for intervention.
Researchers create user-friendly platform that predicts which compounds could become effective obesity treatments.
Knocking out BNIP3 in macrophages reduced adipose inflammation and improved insulin sensitivity in obese mice, revealing a new therapeutic target.
